摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-formyl-6,7-methylenedioxyquinoline | 693263-05-7

中文名称
——
中文别名
——
英文名称
4-formyl-6,7-methylenedioxyquinoline
英文别名
[1,3]Dioxolo[4,5-g]quinoline-8-carbaldehyde
4-formyl-6,7-methylenedioxyquinoline化学式
CAS
693263-05-7
化学式
C11H7NO3
mdl
——
分子量
201.181
InChiKey
BPWXQHWYMGQRNW-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.5
  • 重原子数:
    15
  • 可旋转键数:
    1
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.09
  • 拓扑面积:
    48.4
  • 氢给体数:
    0
  • 氢受体数:
    4

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    4-formyl-6,7-methylenedioxyquinoline四(三苯基膦)钯 吡啶potassium permanganate氯化亚砜 、 sodium hydride 、 三乙胺 、 silver carbonate 、 sodium iodide 作用下, 以 二氯甲烷N,N-二甲基甲酰胺 为溶剂, 反应 10.0h, 生成 13-(2-Dibenzylamino-ethyl)-2,3-dimethoxy-13H-8,10-dioxa-6,13-diaza-cyclopenta[b]chrysen-12-one
    参考文献:
    名称:
    6-Substituted 6H-dibenzo[c,h][2,6]naphthyridin-5-ones: Reversed lactam analogues of ARC-111 with potent topoisomerase I-targeting activity and cytotoxicity
    摘要:
    6-substituted 8,9-dimethoxy-2,3-methylenedioxy-6H-dibenzo[c,h][2,6]naphtyridin-5-ones were synthesized and evaluated for topoisomerase I-targeting activity and cytotoxicity. Several of these reversed lactam analogues of ARC-111 exhibited exceptional cytotoxicity with IC50 values ranging from 0.5 to 3.0 nM. In contrast to topotecan, no resistance was observed with several of these reversed lactam analogues in tumor cell lines that overexpressed the efflux transporters MDR1 or BCRP. (c) 2006 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmc.2005.12.028
  • 作为产物:
    描述:
    3,4-亚甲二氧基苯胺 在 selenium(IV) oxide 、 三氯化铁溶剂黄146 作用下, 以 1,4-二氧六环 为溶剂, 反应 6.0h, 生成 4-formyl-6,7-methylenedioxyquinoline
    参考文献:
    名称:
    2,3-二甲氧基-8,9-亚甲基二氧基-苯并[i]菲啶-12-羧酸的酯和酰胺:有效的细胞毒性和拓扑异构酶I靶向剂。
    摘要:
    5-(2-N,N-二甲基氨基)乙基-8,9-二甲氧基-2,3-亚甲基二氧基-5H-二苯并[c,h] [1,6]萘啶的异常拓扑异构酶I靶向活性和抗肿瘤活性-6-一(ARC-111,topovale)促进了对类似取代的苯并[i]菲啶-12-羧酸酯和酰胺衍生物的研究。在所评估的苯并[i]菲啶-12-羧酸酯中,2-(N,N-二甲基氨基)乙基,2-(N,N-二甲基氨基)-1-甲基乙基和2-(N,N-二甲基氨基) -1,1-二甲基乙基酯在RPMI8402和KB3-1细胞中具有相似的细胞毒性,范围从30到55 nM。几种羧酰胺衍生物具有有效的拓扑异构酶I靶向活性和细胞毒性。2-(N,N-二甲基氨基)乙基,2-(N,N-二乙基氨基)乙基和2-(吡咯烷基-1-基)乙基酰胺是更具细胞毒性的苯并[i]菲啶-12-羧酸衍生物,
    DOI:
    10.1016/j.bmc.2005.07.033
点击查看最新优质反应信息

文献信息

  • Esters and amides of 2,3-dimethoxy-8,9-methylenedioxy-benzo[i]phenanthridine-12-carboxylic acid: Potent cytotoxic and topoisomerase I-targeting agents
    作者:Shejin Zhu、Alexander L. Ruchelman、Nai Zhou、Angela A. Liu、Leroy F. Liu、Edmond J. LaVoie
    DOI:10.1016/j.bmc.2005.07.033
    日期:2005.12
    N-dimethylamino)ethyl-8,9-dimethoxy-2,3-methylenedioxy-5H-dibenzo[c,h][1,6 ]naphthyridin-6-one (ARC-111, topovale) prompted studies on similarly substituted benzo[i]phenanthridine-12-carboxylic ester and amide derivatives. Among the benzo[i]phenanthridine-12-carboxylic esters evaluated, the 2-(N,N-dimethylamino)ethyl, 2-(N,N-dimethylamino)-1-methylethyl, and 2-(N,N-dimethylamino)-1,1-dimethylethyl esters
    5-(2-N,N-二甲基氨基)乙基-8,9-二甲氧基-2,3-亚甲基二氧基-5H-二苯并[c,h] [1,6]萘啶的异常拓扑异构酶I靶向活性和抗肿瘤活性-6-一(ARC-111,topovale)促进了对类似取代的苯并[i]菲啶-12-羧酸酯和酰胺衍生物的研究。在所评估的苯并[i]菲啶-12-羧酸酯中,2-(N,N-二甲基氨基)乙基,2-(N,N-二甲基氨基)-1-甲基乙基和2-(N,N-二甲基氨基) -1,1-二甲基乙基酯在RPMI8402和KB3-1细胞中具有相似的细胞毒性,范围从30到55 nM。几种羧酰胺衍生物具有有效的拓扑异构酶I靶向活性和细胞毒性。2-(N,N-二甲基氨基)乙基,2-(N,N-二乙基氨基)乙基和2-(吡咯烷基-1-基)乙基酰胺是更具细胞毒性的苯并[i]菲啶-12-羧酸衍生物,
  • Topoisomerase-targeting agents
    申请人:LaVoie J. Edmond
    公开号:US20060004008A1
    公开(公告)日:2006-01-05
    The invention provides compounds of formula I or formula II: wherein: the bond represented by — is a single bond or a double bond, and R 1 -R 5 , X, and Y have any of the meanings defined in the specification and their pharmaceutically acceptable salts. The invention also provides pharmaceutical compositions comprising a compound of formula I or II, processes for preparing compounds of formula I or II, intermediates useful for preparing compounds of formula I or II, and therapeutic methods for treating cancer and other topoisomerase related conditions using compounds of formula I or II.
    本发明提供了公式I或公式II的化合物:其中:由—表示的键是单键或双键,R1-R5,X和Y具有规范中定义的任何含义及其药学上可接受的盐。本发明还提供了包含公式I或II化合物的制药组合物,制备公式I或II化合物的方法,用于制备公式I或II化合物的中间体,以及使用公式I或II化合物治疗癌症和其他拓扑异构酶相关疾病的治疗方法。
  • Dimethoxybenzo[i]phenanthridine-12-carboxylic acid derivatives and 6H-dibenzo[c,h][2,6]naphthyridin-5-ones with potent topoisomerase I-targeting activity and cytotoxicity
    作者:Alexander L. Ruchelman、Shejin Zhu、Nai Zhou、Angela Liu、Leroy F. Liu、Edmond J. LaVoie
    DOI:10.1016/j.bmcl.2004.08.070
    日期:2004.11
    The exceptional TOP1-targeting activity and antitumor activity of ARC-111, 1, prompted studies on similarly substituted benzo[i]phenanthridine-12-carboxylic ester and amide derivatives. These studies were extended to include 6-substituted 8,9-dimethoxy-2,3-methylenedioxy-dibenzo [c,h] [2,6]naphthyridin-5-ones, which represent reversed lactam analogues of 1. Several of these analogues retained the potent TOP1-targeting activity and cytotoxicity observed for ARG-111. (C) 2004 Elsevier Ltd. All rights reserved.
  • TOPOISOMERASE-TARGETING AGENTS
    申请人:LaVoie Edmond J.
    公开号:US20090258890A1
    公开(公告)日:2009-10-15
    The invention provides compounds of formula I or formula II: wherein: the bond represented by is a single bond or a double bond, and R 1 -R 5 , X, and Y have any of the meanings defined in the specification and their pharmaceutically acceptable salts. The invention also provides pharmaceutical compositions comprising a compound of formula I or II, processes for preparing compounds of formula I or II, intermediates useful for preparing compounds of formula I or II, and therapeutic methods for treating cancer and other topoisomerase related conditions using compounds of formula I or II.
  • COMPOUNDS AND METHODS FOR INHIBITION OF AP ENDONUCLEASE-1/REDOX FACTOR-1 (HAPE1) ACTIVITY
    申请人:University of Pittsburgh - Of the Commonwealth System of High Education
    公开号:US20140371259A1
    公开(公告)日:2014-12-18
    A method for treating a neoplasm in a subject, comprising co-administering to the subject a therapeutically effective amount of an anticancer agent and a substituted 6,7-methylenedioxy-4-amino-quinoline, or a pharmaceutically acceptable salt or ester thereof.
查看更多